Your browser doesn't support javascript.
loading
Constitutive activation of MEK5 promotes a mesenchymal and migratory cell phenotype in triple negative breast cancer.
Matossian, Margarite D; Hoang, Van T; Burks, Hope E; La, Jacqueline; Elliott, Steven; Brock, Courtney; Rusch, Douglas B; Buechlein, Aaron; Nephew, Kenneth P; Bhatt, Akshita; Cavanaugh, Jane E; Flaherty, Patrick T; Collins-Burow, Bridgette M; Burow, Matthew E.
Afiliação
  • Matossian MD; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • Hoang VT; These authors contributed equally to this work and are shared first authors.
  • Burks HE; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • La J; These authors contributed equally to this work and are shared first authors.
  • Elliott S; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • Brock C; These authors contributed equally to this work and are shared first authors.
  • Rusch DB; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • Buechlein A; These authors contributed equally to this work and are shared first authors.
  • Nephew KP; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • Bhatt A; Department of Medicine, Division of Hematology and Oncology, Tulane University, New Orleans, LA 70118, USA.
  • Cavanaugh JE; Center for Genomics and Bioinformatics, Indiana University, Bloomington, IN 47405, USA.
  • Flaherty PT; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA.
  • Collins-Burow BM; Medical Sciences Program, Indiana University School of Medicine-Bloomington, Bloomington, IN 47405, USA.
  • Burow ME; Department of Pharmacology, Duquesne University School of Pharmacy, Pittsburgh, PA 15282, USA.
Oncoscience ; 8: 64-71, 2021.
Article em En | MEDLINE | ID: mdl-34026925
ABSTRACT
Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer with limited targeted therapeutic options. A defining feature of TNBC is the propensity to metastasize and acquire resistance to cytotoxic agents. Mitogen activated protein kinase (MAPK) and extracellular regulated kinase (ERK) signaling pathways have integral roles in cancer development and progression. While MEK5/ERK5 signaling drives mesenchymal and migratory cell phenotypes in breast cancer, the specific mechanisms underlying these actions remain under-characterized. To elucidate the mechanisms through which MEK5 regulates the mesenchymal and migratory phenotype, we generated stably transfected constitutively active MEK5 (MEK5-ca) TNBC cells. Downstream signaling pathways and candidate targets of MEK5-ca cells were based on RNA sequencing and confirmed using qPCR and Western blot analyses. MEK5 activation drove a mesenchymal cell phenotype independent of cell proliferation effects. Transwell migration assays demonstrated MEK5 activation significantly increased breast cancer cell migration. In this study, we provide supporting evidence that MEK5 functions through FRA-1 to regulate the mesenchymal and migratory phenotype in TNBC.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article